SEC Info - EyePoint Pharmaceuticals, Inc.

SEC Info℠

Home

Help

Please Sign In

EyePoint Pharmaceuticals, Inc. – ‘8-K’ for 9/29/22

On: Thursday, 9/29/22, at 7:05am ET · For: 9/29/22 · Accession #: 950170-22-18990 · File #: 0-51122

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/29/22  EyePoint Pharmaceuticals, Inc.    8-K:8,9     9/29/22   11:196K                                   Donnelley … Solutions/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     54K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     22K 
 6: R1          Document And Entity Information                     HTML     45K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- eypt-20220929_htm                   XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 5: EX-101.LAB  XBRL Labels -- eypt-20220929_lab                     XML     40K 
 3: EX-101.PRE  XBRL Presentations -- eypt-20220929_pre              XML     31K 
 4: EX-101.SCH  XBRL Schema -- eypt-20220929                         XSD     11K 
10: JSON        XBRL Instance as JSON Data -- MetaLinks               11±    17K 
11: ZIP         XBRL Zipped Folder -- 0000950170-22-018990-xbrl      Zip     18K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C:

8-K

i 0001314102 i false00013141022022-09-292022-09-29

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): i September 29, 2022

i EyePoint Pharmaceuticals, Inc.

(Exact name of Registrant as Specified in Its Charter)


i Delaware	i 000-51122	i 26-2774444
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

i 480 Pleasant Street
i Watertown, i Massachusetts		i 02472
(Address of Principal Executive Offices)		(Zip Code)

Registrant’s Telephone Number, Including Area Code: i (617) i 926-5000

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
i Common Stock, par value $0.001	i EYPT	i The NASDAQ Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On September 29, 2022, EyePoint Pharmaceuticals, Inc. issued a press release announcing the first patient dosed in phase 2 clinical trial of EYP-1901 for the treatment of non-proliferative diabetic retinopathy (“NPDR”). A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.


Exhibit No.		Description
99.1		Press Release of EyePoint Pharmaceuticals, Inc. dated September 29, 2022
104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			EYEPOINT PHARMACEUTICALS, INC.

Date:	September 29, 2022	By:	/s/ *George O. Elston*
			George O. Elston Chief Financial Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	9/29/22	None on these Dates
		List all Filings

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/09/23  EyePoint Pharmaceuticals, Inc.    S-8         1/09/23    4:124K                                   Donnelley … Solutions/FA

↑Top

Filing Submission 0000950170-22-018990 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)